quality of life and outcomes

Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting patients’ quality of life and employability....

Background: Multiple Sclerosis (MS) specialist nurses are an integral part of the multidisciplinary health care team of people with MS. However, changes in traditional funding...

Background: Multiple Sclerosis (MS) is a debilitating neurological disease that is three times more likely to impact women. Gender is a key social determinant of...

Background: At the start of the SARS-CoV-2 (COVID-19) pandemic there was uncertainty among Multiple Sclerosis (MS) patients about starting or continuing Disease Modifying Therapies (DMTs)....

Background: Multiple sclerosis (MS) clinical trials often include patient-reported outcomes (PROs) to quantify treatment effects not addressed by standard clinical measures. Regulatory guidance stipulates that...

Background: Pain and fatigue are highly prevalent in multiple sclerosis (MS) and are associated with adverse outcomes spanning the physical, social, and psychological domains. There...

Background: The I Can Do It, You Can Do It (ICDI) national model was initiated by the U.S. department of Health and Human Services Office...

Background: Fatigue is among the most frequent and disabling symptoms in RMS patients. Objectives: To measure multiple sclerosis (MS) fatigue and its impact on daily...

Background: Social stigma is a common experience among persons with multiple sclerosis (PwMS), and it may impact daily functioning, quality of life, and depression. However,...

Background: Multiple Sclerosis (MS) is well known to reduce work productivity and adversely affect usual activities. Although previous studies based on cross-sectional data have identified...

Background: Employers offer a variety of absence benefits. It is unknown how benefit design impacts the use of the benefits, the length of the leaves,...

Background: Johns Hopkins Specialty Pharmacy provides clinical services for eligible multiple sclerosis (MS) patients on oral and self-injectable disease modifying therapies (DMTs) at the Johns...

Background: Sphingosine-1-phosphate receptor modulators (S1Ps), a class of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS), are cell-trafficking inhibitors that have been shown to have...

Background: MS-CQI is the first multi-center improvement research collaborative for MS care. MS-CQI was a three-year study (2018-2020) to evaluate system-level performance variation and improve...

Background: Good communication between patients and their health care provider (HCP) is essential for shared decision making (SDM). We developed a decision support tool (MS-SUPPORT)...

Background: MS-CQI is the first multicenter improvement research collaborative for MS. MS-CQI was a three-year study (2018-2020) of variation in outcomes, and leverages benchmarking, site...

Background: Multiple sclerosis (MS) is a chronic progressive disease, affecting a broad range of important functions. In order to accurately measure disease severity among people...

Background: There are more than 20 disease modifying therapies (DMTs) approved for treatment of Multiple Sclerosis. Previous studies in the same population cohort, treated with...

Background: Walking impairment is one of the hallmark symptoms of persons with multiple sclerosis (PwMS) and affects activities of daily living and their quality of...

Background: Assessment of self-efficacy has been a focus of Can Do MS programs given prior research showing associations between higher self-efficacy and improved motivation, psychological...

Background: Vascular comorbidities are prevalent in the multiple sclerosis (MS) population and can contribute to adverse health outcomes in persons with MS (PwMS). Characterizing the...

Background: Fatigue is a common symptom experienced by patients with Multiple Sclerosis (MS); and, the impact of fatigue on work productivity has been documented. However,...

Background: Multiple Sclerosis is central demyelinating disease that often results in visible motor and coordination or ambulation impact and examination defined visual or sensory disturbance,...

Background: Multiple Sclerosis is a central demyelinating disease that often results in visible motor and coordination or ambulation impact and examination defined visual or sensory...

Background: Symptom management, an important component of MS care, can be achieved by using a patient app tool to manage symptoms and track/store symptom issues...

Background: iConquerMS is a multiple sclerosis (MS) participant-powered research network (PPRN), dedicated to engaging people affected by MS and researchers. iConquerMS participants complete baseline and...

Background: Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system that results in progressive and irreversible disability, with MS-related fatigue reported...

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis (MS)-related symptoms as a proxy for disease severity using...

Background: Living with MS has been particularly challenging during the pandemic; from the emotional and physical toll, to fears about catching the virus, questions about...

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care providers, and care partners will benefit...

Background: Patient-reported outcomes (PROs) responses can be used to measure patients’ health status, functioning, quality of life, and therapeutic response. Objectives: The objective of this...

Background: MS-CQI is the first multi-center improvement research collaborative for MS care. MS-CQI was a three-year study (2018-2020) to evaluate system-level performance variation and improve...

Background: Multiple sclerosis (MS) is characterized by an unpredictable course of neurological symptoms that are thought to be exacerbated by stress and negatively impact quality...

Background: Although fatigue is one of the most common symptoms of multiple sclerosis (MS) and several patient-reported outcome (PRO) instruments assess MS-related fatigue, few PROs...

Background: Disease-modifying therapy (DMT) has demonstrated benefits for patients in reducing relapse rates, disability progression, and new/enlarging MRI lesions. Most patients receive DMT from a...

Background: Multiple sclerosis (MS) is a chronic progressive neurological disease diagnosed commonly between 20-50 years of age, with over 2.3 million people living with MS...

Background: Multiple Sclerosis (MS) is a chronic disease for which there are multiple disease modifying therapies and symptomatic medications. Impaired self-efficacy of medication management can...

Direct cost associated with Multiple sclerosis: A Population-Based Study 1997-2017 Background: Multiple sclerosis (MS) is a chronic neurological disease often described as the most common...